BioSpace News Archive

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced financial results for the fourth quarter and full-year ended December 31, 2020.

Radius Health, Inc., reported its financial results for the fourth quarter ended December 31, 2020 as well as full year 2020 results.

Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today that it has appointed Michael-Bryant Hicks as Executive Vice President, General Counsel, and Corporate Secretary. Hicks will be based in Apria’s corporate headquarters in Indianapolis. a

Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board of Directors Initiated dosing of adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10 Initiated Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease Ended 2020 with strong cash position of $512 million, and raised additional $250 million in early 2021

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced a strategic collaboration with Tempus to leverage the company’s patient-derived organoid biological modeling platform to strengthen Zentalis’ discovery and research capabilities.

—ORLADEYO™ (berotralstat) now approved in U.S. and Japan; EU approval expected in Q2— —Dose-ranging trial of BCX9930 has fully enrolled 16 PNH patients; Data to be presented at R&D day March 22 — —Company adds $325 million in financing in Q4 2020; Year-end cash of $303 million provides cash runway into 2023—

BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the initiation of the Phase 2 PLACIDITY trial of BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”)

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it has also acquired TX Services, LLC, provider of TX Connect, as part of its acquisition of TransChart in January 2021.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau as well as Dr. David Nutt, one of the Company’s lead DMT consultants, will be discussing the Company’s New DMT Stroke Clinical Research Program at the upcoming Psychedelic Capital Virtual Investment Conference,

Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021 ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis Public Offering of $103.5M in January 2021 Strengthens Balance Sheet